Literature DB >> 2684472

Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part I).

P Veng-Pedersen1.   

Abstract

A mean time parameter in pharmacokinetics defines the average time taken for 1 or more kinetic events to occur. Due to the complexity of the subject, a great number of different mean time parameters may be defined. Three of these parameters which appear to be of greatest interest are discussed: mean residence time (MRT), mean transit time (MTT) and mean arrival time (MAT). Formal definitions for these parameters are presented and various methods of evaluating them are described. The concepts of kinetic spaces, of importance in dealing with mean time parameters, are broadly defined. The discussion of the theory behind mean time parameters begins generally with fundamental core relationships, valid for both stochastic and non-stochastic systems, and successively introduces increasing degrees of kinetic specificity, ending with a discussion of mean time parameters of specific pharmacokinetic models. The limitations and assumptions involved in the use of mean time parameters in the various models are highlighted, with examples to clarify the concepts discussed. Area under the moment curve/area under the concentration-time curve (AUMC/AUC), commonly used as a definition for the MRT of drug molecules in the body, should not serve as a definition but should instead be considered as a method of evaluating this parameter. The literature on mean time parameters as they relate to absorption, distribution, elimination, metabolites, dosing times and drug accumulation is discussed. The clinical implications of mean time parameters are also considered, particularly in relation to the prediction, evaluation and interpretation of pharmacokinetic data.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2684472     DOI: 10.2165/00003088-198917050-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  16 in total

1.  The relevance of residence time theory to pharmacokinetics.

Authors:  M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Noncompartmental versus compartmental modelling in clinical pharmacokinetics.

Authors:  W R Gillespie
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

3.  Estimation of permanence time, exit time, dilution factor, and steady-state volume of distribution.

Authors:  J Mordenti; A Rescigno
Journal:  Pharm Res       Date:  1992-01       Impact factor: 4.200

4.  Evaluation of hepatic function using the pharmacokinetics of a therapeutically administered drug. Application to the immunosuppressant cyclosporin.

Authors:  W Weber; M Looby; J Brockmöller
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

5.  Effect of polyaspartic acid on pharmacokinetics of gentamicin after single intravenous dose in the dog.

Authors:  T Whittem; K Parton; K Turner
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  Assessment of exposure to PCB 153 from breast feeding and normal food intake in individual children using a system approach model.

Authors:  Tomáš Trnovec; Ladislav Dedík; Todd A Jusko; Kinga Lancz; Lubica Palkovičová; Anton Kočan; Eva Šovčíková; Soňa Wimmerová; Juraj Tihányi; Henrieta Patayová; Irva Hertz-Picciotto
Journal:  Chemosphere       Date:  2011-11-01       Impact factor: 7.086

7.  Mean remaining life span: a new clinically relevant parameter to assess the quality of transfused red blood cells.

Authors:  Denison J Kuruvilla; Demet Nalbant; John A Widness; Peter Veng-Pedersen
Journal:  Transfusion       Date:  2014-02-24       Impact factor: 3.157

8.  The non-compartmental steady-state volume of distribution revisited.

Authors:  Wojciech Jawień; Jan Kobierski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-01-03       Impact factor: 2.745

9.  Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin.

Authors:  Peter Veng-Pedersen; Kevin J Freise; Robert L Schmidt; John A Widness
Journal:  J Pharm Pharmacol       Date:  2008-10       Impact factor: 3.765

10.  Kinetics of atrial natriuretic peptide in young and elderly subjects.

Authors:  A C Tan; T L Jansen; E F Termond; F G Russel; T Thien; P W Kloppenborg; T J Benraad
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.